Last reviewed · How we verify

Efadermin (lithium succinate)

unknown active

Efadermin (generic name: lithium succinate) is a lithium succinate drug. It is currently in unknown development.

Efadermin is thought to work by modulating lithium levels in the body, which can affect various cellular processes.

Efadermin, also known as lithium succinate, is a small molecule drug in the lithium succinate class. Its mechanism of action and target are unknown, and it has not been approved by the FDA for any indications. The commercial status of efadermin is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine the safety and efficacy of this compound. As a result, key safety considerations and approved indications are currently unavailable.

At a glance

Generic namelithium succinate
Drug classlithium succinate
Therapeutic areaOther
Phaseunknown

Mechanism of action

In simple terms, efadermin is believed to help regulate the amount of lithium in the body, which can then influence how cells function. This can have a range of effects on the body, but the exact mechanisms are not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Efadermin

What is Efadermin?

Efadermin (lithium succinate) is a lithium succinate drug.

How does Efadermin work?

Efadermin is thought to work by modulating lithium levels in the body, which can affect various cellular processes.

What is the generic name of Efadermin?

lithium succinate is the generic (nonproprietary) name of Efadermin.

What drug class is Efadermin in?

Efadermin belongs to the lithium succinate class. See all lithium succinate drugs at /class/lithium-succinate.

What development phase is Efadermin in?

Efadermin is in unknown.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing